New CEO for Glauconix Biosciences

Glauconix Biosciences has  announced the appointment of Kimberly Southern to the position of Chief Executive Officer and member of the Board of Directors, effective immediately. Southern previously held the position of Chief Operating Officer.

Since joining the company in May, Southern has further developed the corporate vision and strategy, most notably the company’s decision to focus on the development of additional bioengineered human 3D tissue models to support needs beyond glaucoma. The company has plans to expand their patented technology to additional ocular tissues and other areas of significant unmet needs, such as lung, kidney and skin tissue.

“Kim has demonstrated a willingness to roll up her sleeves to strengthen the operation of the company,” says board member Richard Frederick, “develop a long-term strategy and grow the team, allowing the founder, Karen Torrejon, to focus on the continued development of the game-changing technology. The board is pleased to elevate her to the position of CEO.”

Dr. Karen Torrejon, Founder and CSO, will manage and execute the company’s development efforts. “Over the last six months,” says Torrejon, ”working side-by-side with Kim, it is clear to me that her vision, integrity and ability to leverage the strengths of the team, align with the core mission of the company. I am very excited and look forward to spending more of my time on further expansion of our core technology while Kim focuses on the implementation and execution of our vision.”

“Glauconix Biosciences is one of those companies that has a unique platform technology that supports expansion into many different markets, and I am honored to have been chosen to lead the company,” says Southern. “The opportunity ahead for us is significant, but to maximize it, we must focus clearly and continue to innovate. A big part of my job is to accelerate our ability to develop additional models and bring them to the market more quickly.”

Be the first to comment on "New CEO for Glauconix Biosciences"

Leave a comment

Your email address will not be published.